经皮冠状动脉介入术围术期合并脑出血的抗栓治疗进展  

Management of Antithrombotic Therapy for Perioperative Intracerebral Hemorrhage in Percutaneous Coronary Intervention

作　　者：刘越[1] 袁晋青[1] 

机构地区：[1]北京协和医学院中国医学科学院国家心血管病中心阜外医院心内科,北京100037

出　　处：《心血管病学进展》2017年第4期367-371,共5页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金(81170194);"十三五"国家重点研发计划项目(2016YFC1301301)

摘　　要：抗栓治疗在预防和治疗缺血事件发生的同时,又增加了经皮冠状动脉介入术围术期脑出血的风险。脑出血与多种危险因素有关,虽然发生率低,但致残率、致死率高。急性期是否需要停用抗栓药物,停用后是否需要恢复以及何时恢复抗栓治疗,目前国内外尚无统一意见。现结合最新研究进展和相关指南,就经皮冠状动脉介入术围术期脑出血急性期及恢复期抗栓治疗策略进行综述。The wide use of antithrombotic drugs for the prevention and treatment of thromboembolic events has increased intracerebral hemorrhage in patients undergoing percutaneous coronary interventions.Intracerebral hemorrhage is associated with various risk factors,though rare,which lead to great disability and high mortality.There are diverse opinions upon the necessity for withdrawal of antithrombotic drugs and the indications and optimal timing of resumption.The focus of this review,based on recent researches and guidelines,is to discuss the management of antithrombotic therapy during intracerebral hemorrhage complicating percutaneous coronary interventions.

关 键 词：经皮冠状动脉介入术 脑出血 抗栓治疗 治疗策略 

分 类 号：R541.4[医药卫生—心血管疾病] R743.34[医药卫生—内科学]